New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Review of Clinical Immunology

• Publication date

  2018-03-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/1744666X.2018.1454835PMID 29557200
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real‐world Canadian dermatology clinics: a multicenter retrospective study

  2018cited by this paper
• Exposure to biological therapies during conception and pregnancy: a systematic review

  2018cited by this paper
• Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy

  2017cited by this paper
• Risankizumab versus ustekinumab for moderate‐to‐severe plaque psoriasis

  2017cited by this paper
• Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

  2017cited by this paper
• Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases

  2017cited by this paper
• Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry

  2017cited by this paper
• Inducción de anticuerpos y enfermedades autoinmunes en pacientes con psoriasis tratados con fármacos anti-TNFα

  2017cited by this paper
• Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials

  2017cited by this paper
• Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA

  2017cited by this paper
• Induction of Autoantibodies and Autoimmune Diseases in Patients with Psoriasis Receiving Tumor Necrosis Factor Inhibitors.

  2017cited by this paper
• Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial

  2017cited by this paper
• Tumour necrosis factor antagonist‐induced lupus: a Critically Appraised Topic

  2017cited by this paper
• Risankizumab versus Ustekinumab for Moderate‐to‐Severe Plaque Psoriasis

  2017cited by this paper
• Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials

  2017cited by this paper
• Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.

  2017cited by this paper
• Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus classic therapies: Prospective meta‐analysis of Psonet registries

  2017cited by this paper
• Short‐term efficacy and safety of new biological agents targeting the interleukin‐23–T helper 17 pathway for moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis

  2017cited by this paper
• Update on biologic safety for patients with psoriasis during pregnancy

  2017cited by this paper
• British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017

  2017cited by this paper
• Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

  2017cited by this paper
• Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections

  2017cited by this paper
• Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants

  2017cited by this paper
• Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study

  2016cited by this paper
• Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients.

  2016cited by this paper
• Premedication prevents infusion reactions and improves retention rate during infliximab treatment

  2016influential reference
• Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

  2016cited by this paper
• Management of psoriasis patients with hepatitis B or hepatitis C virus infection.

  2016influential reference
• Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

  2016cited by this paper
• Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS.

  2016cited by this paper
• Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.

  2016cited by this paper
• Biologic Agents and Tuberculosis

  2016influential reference
• Safety of secukinumab in the treatment of psoriasis

  2016cited by this paper
• A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

  2016cited by this paper
• Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review

  2016influential reference
• Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest

  2015cited by this paper
• Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial

  2015cited by this paper
• Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5‐year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry

  2015cited by this paper
• Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.

  2015influential reference
• Are Anti-TNF-α Agents Safe for Treating Psoriasis in Hepatitis C Virus Patients with Advanced Liver Disease? Case Reports and Review of the Literature

  2015cited by this paper
• Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection

  2015cited by this paper
• Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

  2015cited by this paper
• Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic

  2015cited by this paper
• Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis

  2015cited by this paper
• Autoantibodies in psoriatic patients treated with anti‐TNF‐α therapy

  2014influential reference
• Inflammation, Atherosclerosis and Coronary Artery Disease

  2014cited by this paper
• Antidrug antibodies in psoriasis: a systematic review

  2014cited by this paper
• Secukinumab in plaque psoriasis--results of two phase 3 trials.

  2014influential reference
• Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

  2014cited by this paper
• Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort

  2014cited by this paper
• From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.

  2014cited by this paper
• Demyelination in a patient receiving ustekinumab for refractory Crohn's disease.

  2014cited by this paper
• Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis

  2014cited by this paper
• Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.

  2014cited by this paper
• Clinical management of paradoxical psoriasiform reactions during TNF- α therapy.

  2014cited by this paper
• Reacciones psoriasiformes paradójicas durante el tratamiento con terapia anti-factor de necrosis tumoral. Manejo clínico

  2014cited by this paper
• A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy.

  2014cited by this paper
• Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study.

  2013cited by this paper
• Selective TNF-α inhibitor-induced injection site reactions

  2013cited by this paper
• Re‐evaluation of the risk for major adverse cardiovascular events in patients treated with anti‐IL‐12/23 biological agents for chronic plaque psoriasis: a meta‐analysis of randomized controlled trials

  2013cited by this paper
• A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial

  2013cited by this paper
• Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.

  2013cited by this paper
• The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

  2013cited by this paper
• Risk of cancer in psoriasis: a systematic review and meta‐analysis of epidemiological studies

  2013cited by this paper
• Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting

  2013cited by this paper
• Global epidemiology of psoriasis: a systematic review of incidence and prevalence.

  2013cited by this paper
• Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface‐antigen‐negative anti‐HBs‐positive patient

  2013cited by this paper
• From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis.

  2013influential reference
• Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment.

  2012cited by this paper
• Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy.

  2012cited by this paper
• Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study.

  2012cited by this paper
• Ustekinumab for the treatment of HIV psoriasis

  2012cited by this paper
• Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.

  2012cited by this paper
• Use of anti‐tumor necrosis factor‐α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan

  2012cited by this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry

  2012cited by this paper
• Differential Risk of Tuberculosis Reactivation among Anti-TNF Therapies Is Due to Drug Binding Kinetics and Permeability

  2012cited by this paper
• Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management.

  2012cited by this paper
• The safety of ustekinumab treatment in patients with moderate‐to‐severe psoriasis and latent tuberculosis infection

  2012cited by this paper
• An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.

  2012cited by this paper
• Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center Study

  2012cited by this paper
• Reactivation of Hepatitis B after Administration of Anti-TNFα in a Patient with Psoriasis

  2012cited by this paper
• Hepatitis-B-Reaktivierung unter TNF-α-Blocker- Therapie mit Adalimumab bei Psoriasis-Arthritis

  2012cited by this paper
• Efficacy of Hepatitis B Vaccination and Revaccination and Factors Impacting on Response in Patients With Inflammatory Bowel Disease

  2012cited by this paper
• [Hepatitis-B reactivation during treatment with tumor necrosis factor-α blocker adalimumab in a patient with psoriasis arthritis].

  2012cited by this paper
• Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

  2011cited by this paper
• Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

  2011cited by this paper
• The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study

  2011cited by this paper
• Injection‐site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization

  2011cited by this paper
• Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.

  2011cited by this paper
• Adverse effects of biologics: a network meta-analysis and Cochrane overview.

  2011cited by this paper
• TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome.

  2011cited by this paper
• Spondylarthritis presenting with an allergic immediate systemic reaction to adalimumab in a woman: a case report

  2011cited by this paper
• Pesquisa de autoanticorpos em pacientes com artrite psoriásica sob terapia anti-TNFα

  2010cited by this paper
• Autoantibodies in patients with psoriatic arthritis on anti-TNFα therapy.

  2010influential reference
• Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

  2010cited by this paper
• Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.

  2010cited by this paper
• Neurological adverse events associated with anti-tumor necrosis factor alpha treatment

  2010cited by this paper
• Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity.

  2010cited by this paper
• Risk factors for idiopathic orbital inflammation: a case–control study

  2010cited by this paper

• Adverse Drug Reactions to Biologic Drugs in the Treatment of Psoriasis

  2026cites this paper
• pH Responsive Trimethyl Chitosan Nanogels Enhance Site-Specific Fluocinolone Acetonide Delivery for Psoriasis Therapy

  2026cites this paper
• Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study

  2025cites this paper
• Topical histone Deacetylase Inhibitor Remetinostat improves IMQ-induced psoriatic dermatitis via suppressing dendritic cell maturation and keratinocyte differentiation and inflammation.

  2024cites this paper
• Saffron as a Promising Therapy for Inflammatory Bowel Disease

  2024cites this paper
• Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting

  2022cites this paper
• Discovering Novel Biomarkers Associated with the Pathogenesis of Psoriasis: Evidence from Bioinformatic Analysis

  2022cites this paper
• Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection

  2021cites this paper
• Interleukin 12/23 Inhibitors

  2021cites this paper
• Comparative Safety and Benefit-Risk Profile of Biologics and Oral Treatments for Moderate-to-Severe Plaque Psoriasis: a Network Meta-Analysis of Clinical Trial Data.

  2021cites this paper
• Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis: Consensus Statements for the United Arab Emirates

  2021cites this paper
• Principios de psoriasis y enfoque terapéutico en embarazo: revisión de literatura

  2020cites this paper
• Therapeutic Potential of TNF-α Inhibition for Alzheimer’s Disease Prevention

  2020influential citation
• Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate‐to‐severe psoriasis after 1 year of treatment: Real‐world practice

  2020cites this paper
• Interleukin-17 and lupus: enough to be a target? For which patients?

  2019cites this paper
• Rethinking Pharmacological Nomenclature.

  2018cites this paper